Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
107.44
+0.99 (+0.93%)
Official Closing Price
Updated: 7:00 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
99
100
Next >
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
↗
October 13, 2025
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
Via
MarketBeat
Topics
Artificial Intelligence
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
October 13, 2025
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early...
Via
MarketMinute
Topics
Economy
Government
Stocks
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
↗
October 13, 2025
Via
Benzinga
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
↗
October 13, 2025
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via
The Motley Fool
Topics
ETFs
Government
World Trade
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
October 12, 2025
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
October 10, 2025
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine...
Via
MarketMinute
Topics
Bonds
Economy
World Trade
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments
↗
October 10, 2025
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Via
Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
October 09, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
October 09, 2025
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...
Via
MarketMinute
Topics
Economy
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
October 09, 2025
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This...
Via
MarketMinute
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
October 09, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...
Via
MarketMinute
Topics
Economy
Intellectual Property
Retirement
Behind the Scenes of Merck & Co's Latest Options Trends
↗
October 09, 2025
Via
Benzinga
5 Healthcare Plays Powering the Sector’s Big Comeback
↗
October 09, 2025
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via
MarketBeat
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
October 09, 2025
From
Merck & Co., Inc.
Via
Business Wire
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
October 09, 2025
From
Merck Sharp & Dohme
Via
Business Wire
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 08, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccine
↗
October 07, 2025
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via
Benzinga
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
↗
October 07, 2025
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via
Investor's Business Daily
Merck Completes Acquisition of Verona Pharma
October 07, 2025
From
Merck & Co., Inc.
Via
Business Wire
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
October 06, 2025
From
Merck Sharp & Dohme
Via
Business Wire
1 Monster Stock in the Making to Buy and Hold
↗
October 05, 2025
This biotech company was relatively unknown a few years ago.
Via
The Motley Fool
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets
↗
October 03, 2025
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Merck & Co's Options: A Look at What the Big Money is Thinking
↗
October 03, 2025
Via
Benzinga
U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers
October 02, 2025
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been...
Via
MarketMinute
Topics
Bonds
Economy
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
↗
October 02, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via
Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
↗
October 02, 2025
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.
Via
The Motley Fool
Topics
Stocks
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
October 02, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...
Via
TokenRing AI
Topics
Artificial Intelligence
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
October 02, 2025
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a...
Via
MarketMinute
Wall Street Holds Firm Despite Shutdown and Weak Jobs Data
↗
October 02, 2025
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via
Chartmill
Topics
Economy
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
↗
October 01, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via
Benzinga
Topics
Government
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.